C1Q	B:C1167938
Assay	I:C1167938
Results	O
in	O
Complement	B:C4084772
-	I:C4084772
Dependent	I:C4084772
Cytotoxicity	I:C4084772
Crossmatch	B:C0855279
Negative	B:C0205160
Renal	B:C0022671
Transplant	I:C0022671
Candidates	B:C1257890
with	O
Donor	B:C0003241
-	I:C0003241
Specific	I:C0003241
Antibodies	I:C0003241
:	O
High	O
Specificity	O
but	O
Low	O
Sensitivity	O
When	O
Predicting	O
Flow	B:C0201644
Crossmatch	I:C0201644
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
the	O
association	O
of	O
positive	B:C1446409
flow	B:C0201644
cross	I:C0201644
match	I:C0201644
(	O
FXM	B:C0201644
)	O
and	O
C1q	B:C1167938
-	I:C1167938
SAB	I:C1167938
.	O

In	O
this	O
observational	B:C1518527
,	O
cross-sectional	B:C0010362
,	O
and	O
comparative	B:C1579762
study	I:C1579762
,	O
patients	O
included	O
had	O
negative	B:C0205160
AHG	B:C0855279
-	I:C0855279
CDC-XM	I:C0855279
and	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
(	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
)	O
and	O
were	O
tested	O
with	O
FXM	B:C0201644
.	O

All	O
pretransplant	B:C0229671
sera	I:C0229671
were	O
tested	O
with	O
C1q	B:C1167938
-	I:C1167938
SAB	I:C1167938
assay	I:C1167938
.	O

A	O
total	O
of	O
50	O
donor	B:C0013018
/	O
recipient	B:C1709854
evaluations	B:C0220825
were	O
conducted	O
;	O
half	O
of	O
them	O
had	O
at	O
least	O
one	O
C1q	B:C1717709
+	I:C1717709
Ab	I:C1717709
(	O
n	O
=	O
26	O
,	O
52	O
%	O
)	O
.	O

Ten	O
patients	O
(	O
20.0	O
%	O
)	O
had	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
C1	B:C1717709
q	I:C1717709
+	I:C1717709
Ab.	I:C1717709
Twenty	O
-	O
five	O
(	O
50	O
%	O
)	O
FXMs	B:C0201644
were	O
positive	B:C1446409
.	O

Factors	O
associated	O
with	O
a	O
positive	B:C1446409
FXM	B:C0201644
were	O
the	O
presence	B:C0150312
of	O
C1q	B:C1717709
+	I:C1717709

Ab	I:C1717709
(	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
C1	B:C1717709
q	I:C1717709
+	I:C1717709
Ab	I:C1717709
:	O
OR	O
27	O
,	O
2.80-259.56	O
,	O
P	O
=	O
0.004	O
,	O
and	O
no	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
C1q	B:C1717709
+	I:C1717709
Ab	I:C1717709
:	O
OR	O
5	O
,	O
1.27	O
-19.68	O
,	O
P	O
=	O
0.021	O
)	O
and	O
the	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
LABScreen	B:C0078968
-	I:C0078968
SAB	I:C0078968
MFI	O
(	O
OR	O
1.26	O
,	O
95	O
%	O
CI	O
1.06	O
-	O
1.49	O
,	O
P	O
=	O
0.007	O
)	O
.	O

The	O
cutoff	O
point	O
of	O
immunodominant	B:C0078968
LABScreen	I:C0078968
SAB	I:C0078968
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
-	O
MFI	O
with	O
the	O
greatest	O
sensitivity	O
and	O
specificity	O
to	O
predict	O
FXM	B:C0201644
was	O
2,300	O
(	O
sensitivity	O
:	O
72	O
%	O
and	O
specificity	O
:	O
75	O
%	O
)	O
.	O

For	O
FXM	B:C0201644
prediction	O
,	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
C1q	B:C1717709
+	I:C1717709

Ab	I:C1717709
was	O
the	O
most	O
specific	O
(	O
95.8	O
%	O
,	O
85-100	O
)	O
and	O
the	O
combination	O
of	O
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
-	O
MFI	O
>	O
2,300	O
and	O
C1q	B:C1717709
+	I:C1717709

Ab	I:C1717709
was	O
the	O
most	O
sensitive	O
(	O
92.0	O
%	O
,	O
79.3-100	O
)	O
.	O

C1	B:C1717709
q	I:C1717709
+	I:C1717709
Ab	I:C1717709
and	O
LABScreen	B:C0078968
SAB	I:C0078968
donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
-	O
MFI	O
were	O
significantly	O
associated	O
with	O
FXM	B:C0201644
.	O

donor	B:C0003241
specific	I:C0003241
antibodies	I:C0003241
C1q	B:C1717709
+	I:C1717709

Ab	I:C1717709
was	O
highly	O
specific	O
but	O
with	O
low	O
sensitivity	O
.	O

